Molybdate Attenuates Lipid Accumulation in the Livers of Mice Fed a Diet Deficient in Methionine and Choline
| Autor: | Doug-Young Ryu, Seung-Woo Lee, Je Kyung Seong, Ki-Hoan Nam |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Antioxidant medicine.medical_treatment Pharmaceutical Science Protein oxidation medicine.disease_cause 03 medical and health sciences chemistry.chemical_compound Methionine Non-alcoholic Fatty Liver Disease Malondialdehyde Internal medicine medicine Animals Choline Aspartate Aminotransferases Molybdenum Pharmacology Catabolism Fatty liver Alanine Transaminase General Medicine Lipid Metabolism medicine.disease Choline Deficiency Diet Mice Inbred C57BL 030104 developmental biology Endocrinology Liver chemistry Steatosis Oxidative stress |
| Zdroj: | Biological and Pharmaceutical Bulletin. 41:1203-1210 |
| ISSN: | 1347-5215 0918-6158 |
| Popis: | Both lipid accumulation and oxidative stress are major pathologic contributors to the development of hepatic steatosis. Treatment with molybdate reduces hepatic levels of lipids in diabetic rats. Potential activities of molybdate as an antioxidant have also been demonstrated in various animal models. In the present study, we evaluated the effects of sodium molybdate dihydrate (SM) on hepatic steatosis and associated disturbances in a widely used mouse model of the metabolic disease. Male C57Bl/6 mice at 10 weeks of age were fed a diet deficient in methionine and choline (MCD) and bottled water containing SM for four weeks. The SM treatment markedly attenuated MCD-induced accumulation of lipids, mainly triglycerides, in the liver. Lipid catabolic autophagic pathways were activated by SM in the MCD-fed mouse livers, as evidenced by a decreased level of p62 expression. MCD-induced oxidative damage, such as lipid and protein oxidation, was also alleviated by SM in the liver. However, the level of MCD-induced hepatocellular damage was not affected by SM. Taken together, these findings suggest that molybdate can be used in the treatment and prevention of hepatic steatosis without inducing adverse effects in the liver. To the best of our knowledge, this is the first experimental study to investigate the effects of molybdate in non-alcoholic fatty liver disease, and also the first that demonstrates molybdate-induced autophagy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|